These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22533875)

  • 1. Mitigating heterocycle metabolism in drug discovery.
    St Jean DJ; Fotsch C
    J Med Chem; 2012 Jul; 55(13):6002-20. PubMed ID: 22533875
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessing atropisomer axial chirality in drug discovery and development.
    Laplante SR; D Fader L; Fandrick KR; Fandrick DR; Hucke O; Kemper R; Miller SP; Edwards PJ
    J Med Chem; 2011 Oct; 54(20):7005-22. PubMed ID: 21848318
    [No Abstract]   [Full Text] [Related]  

  • 3. A multi-endpoint matched molecular pair (MMP) analysis of 6-membered heterocycles.
    Chang G; Huard K; Kauffman GW; Stepan AF; Keefer CE
    Bioorg Med Chem; 2017 Jan; 25(1):381-388. PubMed ID: 27840138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy.
    Obach RS
    Pharmacol Rev; 2013 Apr; 65(2):578-640. PubMed ID: 23406671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Project ranks billions of drug interactions.
    Reardon S
    Nature; 2013 Nov; 503(7477):449-50. PubMed ID: 24284710
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
    Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
    Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parallel worlds of public and commercial bioactive chemistry data.
    Lipinski CA; Litterman NK; Southan C; Williams AJ; Clark AM; Ekins S
    J Med Chem; 2015 Mar; 58(5):2068-76. PubMed ID: 25415348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs.
    Perola E
    J Med Chem; 2010 Apr; 53(7):2986-97. PubMed ID: 20235539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quo vadis, virtual screening? A comprehensive survey of prospective applications.
    Ripphausen P; Nisius B; Peltason L; Bajorath J
    J Med Chem; 2010 Dec; 53(24):8461-7. PubMed ID: 20929257
    [No Abstract]   [Full Text] [Related]  

  • 10. Predicting biotransformation potential from molecular structure.
    Borodina Y; Sadym A; Filimonov D; Blinova V; Dmitriev A; Poroikov V
    J Chem Inf Comput Sci; 2003; 43(5):1636-46. PubMed ID: 14502498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug rings database with web interface. A tool for identifying alternative chemical rings in lead discovery programs.
    Lewell XQ; Jones AC; Bruce CL; Harper G; Jones MM; McLay IM; Bradshaw J
    J Med Chem; 2003 Jul; 46(15):3257-74. PubMed ID: 12852756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BioCores: identification of a drug/natural product-based privileged structural motif for small-molecule lead discovery.
    Kombarov R; Altieri A; Genis D; Kirpichenok M; Kochubey V; Rakitina N; Titarenko Z
    Mol Divers; 2010 Feb; 14(1):193-200. PubMed ID: 19468851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug metabolites as cytochrome p450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development.
    Callegari E; Kalgutkar AS; Leung L; Obach RS; Plowchalk DR; Tse S
    Drug Metab Dispos; 2013 Dec; 41(12):2047-55. PubMed ID: 23792812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biotransformation reactions of five-membered aromatic heterocyclic rings.
    Dalvie DK; Kalgutkar AS; Khojasteh-Bakht SC; Obach RS; O'Donnell JP
    Chem Res Toxicol; 2002 Mar; 15(3):269-99. PubMed ID: 11896674
    [No Abstract]   [Full Text] [Related]  

  • 15. [Application and development of in vitro metabolism study at early drug discovery stage].
    Wu H; Peng Y; Sun JG; Zhang XY; Zhong YX; Wang GJ
    Yao Xue Xue Bao; 2013 Jul; 48(7):1071-9. PubMed ID: 24133972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
    Palucki M; Higgins JD; Kwong E; Templeton AC
    J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
    [No Abstract]   [Full Text] [Related]  

  • 17. Lead optimization strategies as part of a drug metabolism environment.
    Korfmacher WA
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):481-5. PubMed ID: 12951811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trade-off between accuracy and interpretability for predictive in silico modeling.
    Johansson U; Sönströd C; Norinder U; Boström H
    Future Med Chem; 2011 Apr; 3(6):647-63. PubMed ID: 21554073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The many roles of molecular complexity in drug discovery.
    Méndez-Lucio O; Medina-Franco JL
    Drug Discov Today; 2017 Jan; 22(1):120-126. PubMed ID: 27575998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enantiodivergent synthesis of both enantiomers of marine alkaloids haliclorensin and isohaliclorensin, a constituent of halitulin.
    Zheng JF; Jin LR; Huang PQ
    Org Lett; 2004 Apr; 6(7):1139-42. PubMed ID: 15040742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.